Business Description
Lushang Freda Pharmaceutical Co Ltd
NAICS : 531190
ISIN : CNE000001147
Share Class Description:
SHSE:600223: Class ACompare
Compare
Traded in other countries / regions
600223.China IPO Date
2000-01-13Description
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.31 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | 1.31 | |||||
| Interest Coverage | 6.07 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 5.18 | |||||
| Beneish M-Score | -3.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -30.4 | |||||
| 3-Year EBITDA Growth Rate | -14 | |||||
| 3-Year EPS without NRI Growth Rate | -39.1 | |||||
| 3-Year FCF Growth Rate | -60.5 | |||||
| 3-Year Book Growth Rate | -0.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 43.56 | |||||
| Future 3-5Y Total Revenue Growth Rate | 6.05 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 76.85 | |||||
| 9-Day RSI | 73.15 | |||||
| 14-Day RSI | 69.9 | |||||
| 6-1 Month Momentum % | -4.98 | |||||
| 12-1 Month Momentum % | -25.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.45 | |||||
| Quick Ratio | 2.96 | |||||
| Cash Ratio | 2.38 | |||||
| Days Inventory | 245.99 | |||||
| Days Sales Outstanding | 43.72 | |||||
| Days Payable | 103.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.82 | |||||
| Dividend Payout Ratio | 0.36 | |||||
| Forward Dividend Yield % | 1.82 | |||||
| 5-Year Yield-on-Cost % | 1.82 | |||||
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | 56.56 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.75 | |||||
| Operating Margin % | 6.7 | |||||
| Net Margin % | 5.93 | |||||
| FCF Margin % | 1.42 | |||||
| ROE % | 5.86 | |||||
| ROA % | 3.15 | |||||
| ROIC % | 5.69 | |||||
| ROC (Joel Greenblatt) % | 18.78 | |||||
| ROCE % | 6.91 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.5 | |||||
| Forward PE Ratio | 22.14 | |||||
| PE Ratio without NRI | 29.03 | |||||
| Shiller PE Ratio | 32.16 | |||||
| Price-to-Owner-Earnings | 117.93 | |||||
| PEG Ratio | 58.06 | |||||
| PS Ratio | 1.84 | |||||
| PB Ratio | 2 | |||||
| Price-to-Tangible-Book | 2.18 | |||||
| Price-to-Free-Cash-Flow | 102.96 | |||||
| Price-to-Operating-Cash-Flow | 32.66 | |||||
| EV-to-EBIT | 19.1 | |||||
| EV-to-EBITDA | 19.1 | |||||
| EV-to-Revenue | 1.71 | |||||
| EV-to-FCF | 84.18 | |||||
| Price-to-Projected-FCF | 0.47 | |||||
| Price-to-Median-PS-Value | 2.25 | |||||
| Price-to-Graham-Number | 1.68 | |||||
| Price-to-Net-Current-Asset-Value | 3.62 | |||||
| Price-to-Net-Cash | 8.84 | |||||
| Earnings Yield (Greenblatt) % | 5.24 | |||||
| FCF Yield % | 0.66 | |||||
| Forward Rate of Return (Yacktman) % | 18.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lushang Freda Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,986.449 | ||
| EPS (TTM) (Â¥) | 0.24 | ||
| Beta | 2.24 | ||
| Volatility % | 44.78 | ||
| 14-Day RSI | 69.9 | ||
| 14-Day ATR (Â¥) | 0.375612 | ||
| 20-Day SMA (Â¥) | 7.379 | ||
| 12-1 Month Momentum % | -25.16 | ||
| 52-Week Range (Â¥) | 5.74 - 9.96 | ||
| Shares Outstanding (Mil) | 1,016.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lushang Freda Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lushang Freda Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lushang Freda Pharmaceutical Co Ltd Frequently Asked Questions
What is Lushang Freda Pharmaceutical Co Ltd(SHSE:600223)'s stock price today?
The current price of SHSE:600223 is ¥8.04. The 52 week high of SHSE:600223 is ¥9.96 and 52 week low is ¥5.74.
When is next earnings date of Lushang Freda Pharmaceutical Co Ltd(SHSE:600223)?
The next earnings date of Lushang Freda Pharmaceutical Co Ltd(SHSE:600223) is .
Does Lushang Freda Pharmaceutical Co Ltd(SHSE:600223) pay dividends? If so, how much?
The Dividend Yield %  of Lushang Freda Pharmaceutical Co Ltd(SHSE:600223) is 1.82% (As of Today), Highest Dividend Payout Ratio of Lushang Freda Pharmaceutical Co Ltd(SHSE:600223) was 1.83. The lowest was 0.16. And the median was 0.37. The  Forward Dividend Yield % of Lushang Freda Pharmaceutical Co Ltd(SHSE:600223) is 1.82%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers